| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Dec'17 |
|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | ||||||||
2,491 | 2,776 | 8,578 | 5,279 | 8,942 | 5,618 | 11,258 | 1,298 | 4,180 |
Marketable securities | ||||||||
- | - | 0 | 0 | 2,348 | 14,106 | 16,121 | - | - |
Accounts receivable | ||||||||
769 | 898 | 1,088 | 871 | 628 | 639 | 403 | 352 | 117 |
Prepaid expenses and other current assets | ||||||||
1,009 | 336 | 643 | 416 | 832 | 1,061 | 1,555 | 799 | 677 |
Total current assets | ||||||||
4,269 | 4,010 | 10,309 | 6,566 | 12,750 | 21,424 | 29,337 | 2,449 | 4,974 |
Property and equipment, net | ||||||||
612 | 594 | 501 | 555 | 544 | 604 | 544 | 541 | 601 |
Deferred offering costs | ||||||||
- | - | - | - | - | - | - | 1,725 | - |
TOTAL ASSETS | ||||||||
4,881 | 4,604 | 10,810 | 7,121 | 13,294 | 22,028 | 29,881 | 4,715 | 5,575 |
LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
Current liabilities: | ||||||||
Accounts payable | ||||||||
3,297 | 3,208 | 2,343 | 5,448 | 2,439 | 2,322 | 2,276 | 3,609 | 1,910 |
Accrued expenses | ||||||||
3,323 | 3,670 | 4,553 | 4,053 | 4,520 | 4,364 | 3,818 | 3,843 | 1,957 |
Deferred revenue | ||||||||
- | - | - | - | - | - | - | - | 298 |
Deferred revenue | ||||||||
- | - | - | - | - | - | 42 | 104 | - |
Convertible promissory note to related party | ||||||||
- | - | - | - | - | - | - | 1,277 | - |
Total current liabilities | ||||||||
- | - | - | - | - | - | 6,136 | 8,833 | 4,165 |
Convertible promissory notes to related party, net | ||||||||
- | - | - | - | - | - | - | - | 2,813 |
Derivative liabilities | ||||||||
- | - | - | - | - | - | - | 31 | 369 |
TOTAL LIABILITIES | ||||||||
6,620 | 6,878 | 6,896 | 9,501 | 6,959 | 6,686 | 6,136 | 8,864 | 7,347 |
Commitments and contingencies (Note 7) | ||||||||
- | - | - | - | - | - | 0 | 0 | - |
Redeemable convertible preferred stock (Series B, B-1, B-2, C, D), par value of $0.001 per share; zero and 66,317,000 shares authorized as of December 31, 2018 and December 31, 2017; zero shares issued and outstanding as of December 31, 2018; 53,089,959 shares issued and 53,089,796 shares outstanding as of December 31, 2017 with aggregate liquidation preference of $0 and $140,261 as of December 31, 2018 and December 31, 2017 | ||||||||
- | - | - | - | - | - | - | 111,718 | 111,718 |
Stockholders’ deficit: | ||||||||
Convertible preferred stock (Series A), par value of $0.001 per share; zero and 5,702,450 shares authorized, issued and outstanding as of December 31, 2018 and December 31, 2017 with aggregate liquidation preference of $0 and $7,684 as of December 31, 2018 and December 31, 2017 | ||||||||
- | - | - | - | - | - | - | 7,684 | 7,684 |
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of March 31, 2020, and December 31, 2019; 16,377,587 and 14,887,999 shares issued as of March 31, 2020 and December 31, 2019, respectively; 16,376,735 and 14,887,147 shares outstanding as of March 31, 2020 and December 31, 2019, respectively | ||||||||
2 | 1 | 1 | 1 | 1 | 1 | 1 | - | - |
Additional paid-in capital | ||||||||
230,086 | 222,403 | - | - | - | - | - | - | - |
Additional paid-in capital | ||||||||
- | - | 222,265 | 208,329 | 208,216 | 208,156 | 208,110 | 54,216 | 54,123 |
Treasury stock, at cost; 852 shares of common stock as of March 31, 2020 and December 31, 2019, respectively | ||||||||
11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
Accumulated deficit | ||||||||
-255,779 | -248,630 | -242,304 | -234,662 | -225,834 | -216,767 | -208,318 | -201,719 | -187,249 |
Total Vaccinex, Inc. stockholders’ deficit | ||||||||
-25,702 | -26,237 | -20,049 | -26,343 | -17,628 | -8,621 | -218 | -139,830 | -125,453 |
Noncontrolling interests | ||||||||
23,963 | 23,963 | 23,963 | 23,963 | 23,963 | 23,963 | 23,963 | 23,963 | 11,963 |
TOTAL STOCKHOLDERS’ DEFICIT | ||||||||
-1,739 | -2,274 | 3,914 | -2,380 | 6,335 | 15,342 | 23,745 | -115,867 | -113,490 |
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
4,881 | 4,604 | 10,810 | 7,121 | 13,294 | 22,028 | 29,881 | 4,715 | 5,575 |